Dysport (abobotulinumtoxinA) is a botulinum toxin A produced by the bacteria Clostriudium botulinum. The toxin blocks neuromuscular conduction between nerves and muscles for short-term localized relaxation of the targeted muscle. Dysport has not yet been approved by the FDA to treat urinary incontinence in adults with neurogenic detrusor overactivity (NDO) caused by spinal cord injury or multiple sclerosis (MS), but a current Phase 3 trial for the therapy is recruiting participants.

Prior to the start of the current study, abobotulinumtoxinA was studied in a Phase 2 clinical trial for the treatment of neurogenic detrusor overactivity (NDO) in multiple sclerosis (NCT01357980) .

The expected effects of the botulinum toxin may spread from the area of injection and produce symptoms that could last for several weeks. Swallowing, speaking, and breathing difficulties can be life-threatening.

Other serious adverse reactions that may affect areas not associated with the injection site could include loss of strength and all-over muscle weakness; double vision, blurred vision, and drooping eyelids; speaking problems; loss of bladder control; swallowing difficulties; and breathing problems.

Common side effects reported within the first 12 weeks after treatment include urinary tract infection, urinary retention, presence of blood in the urine, fatigue, and insomnia.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.